MADRID -- Dual antiplatelet therapy (DAPT) didn't improve outcomes after coronary artery bypass grafting (CABG) for an acute coronary syndrome (ACS) but did increase risks, the TACSI randomized trial ...

MADRID, Spain—Adding ticagrelor on top of aspirin alone for 1 year does not lower the incidence of death, MI, stroke, or repeat revascularization in ACS patients who undergo CABG surgery, according to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PARIS -- For ...

Compared with ticagrelor or aspirin alone, 12 months of dual antiplatelet therapy (DAPT) after coronary artery bypass graft surgery is associated with a reduced risk of MACE that persists out to 5 ...

ANAHEIM, CA — A new trial shows the combination of aspirin plus ticagrelor (Brilinta, AstraZeneca) resulted in significant improvement in saphenous vein graft (SVG) patency at 12 months compared with ...

Please provide your email address to receive an email when new articles are posted on . The price of CABG was not associated with adverse outcomes or CMS or patient rankings. Cost was higher at ...

Although CABG remains the revascularization treatment of choice for patients with severely symptomatic or life-threatening coronary artery disease (CAD), 9% to 25% of the patients who have undergone ...

Duration of rheumatoid arthritis and use of corticosteroids were associated with higher risk of adverse outcomes following coronary artery bypass graft (CABG). Patients with rheumatoid arthritis (RA) ...